BE898946A - Nouveaux antagonistes des recepteurs de l'adenosine - Google Patents

Nouveaux antagonistes des recepteurs de l'adenosine

Info

Publication number
BE898946A
BE898946A BE0/212418A BE212418A BE898946A BE 898946 A BE898946 A BE 898946A BE 0/212418 A BE0/212418 A BE 0/212418A BE 212418 A BE212418 A BE 212418A BE 898946 A BE898946 A BE 898946A
Authority
BE
Belgium
Prior art keywords
receptor antagonists
adenosine receptor
xanthine
dipropyl
novel adenosine
Prior art date
Application number
BE0/212418A
Other languages
English (en)
Inventor
S H Snyder
J W Daly
R F Bruns
Original Assignee
Univ Johns Hopkins
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Johns Hopkins filed Critical Univ Johns Hopkins
Publication of BE898946A publication Critical patent/BE898946A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C07D473/08—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

De nouvelles 8-phénylxanthines, comme la 1,3-dipropyl-8-(2-amino-4-chlorophényl)xanthine, la 1,3-dipropyl-8-(2,4-diaminophényl)xanthine, la 8-(2-amino-4-chlorophényl)théophylline et la 1,3-dipropyl-8-phényl-xanthine, sont de puissants antagonistes des récepteurs de l'adénosine. La très haute activité de ces composés permet de les utiliser en concentrations plus faibles que les xanthines déjà connues et ainsi d'atténuer les effets secondaires observés.
BE0/212418A 1983-02-18 1984-02-17 Nouveaux antagonistes des recepteurs de l'adenosine BE898946A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/467,894 US4593095A (en) 1983-02-18 1983-02-18 Xanthine derivatives

Publications (1)

Publication Number Publication Date
BE898946A true BE898946A (fr) 1984-06-18

Family

ID=23857582

Family Applications (1)

Application Number Title Priority Date Filing Date
BE0/212418A BE898946A (fr) 1983-02-18 1984-02-17 Nouveaux antagonistes des recepteurs de l'adenosine

Country Status (10)

Country Link
US (1) US4593095A (fr)
JP (1) JPS59205377A (fr)
BE (1) BE898946A (fr)
CA (1) CA1234804A (fr)
DE (1) DE3406275A1 (fr)
FR (1) FR2541281B1 (fr)
GB (2) GB8403574D0 (fr)
IT (1) IT1196031B (fr)
NL (1) NL8400514A (fr)
SE (1) SE456680B (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4755517A (en) * 1986-07-31 1988-07-05 Warner-Lambert Company Derivatives of xanthine, pharmaceutical compositions and methods of use therefor

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4769377A (en) * 1983-02-18 1988-09-06 The Johns Hopkins University Adenosine receptor antagonists
US4696932A (en) * 1984-10-26 1987-09-29 The United States Of America As Represented By The Department Of Health And Human Services Biologically-active xanthine derivatives
GB8510758D0 (en) * 1985-04-27 1985-06-05 Wellcome Found Compounds
US5017577A (en) * 1986-04-25 1991-05-21 Burroughs Wellcome Co. Methods for treating viral infection
US4772607A (en) * 1986-05-20 1988-09-20 Warner-Lambert Company Dialkenyl derivatives of xanthine, pharmaceutical compositions and methods of use therefor
US4783530A (en) * 1986-11-13 1988-11-08 Marion Laboratories, Inc. 8-arylxanthines
JPS63154687A (ja) * 1986-11-13 1988-06-27 マリオン・ラボラトリーズ・インコーポレーテッド ８ーアリールキサンチン
US5015647A (en) * 1987-04-24 1991-05-14 Burroughs Wellcome Co. Method for treating viral infections
US5032593A (en) * 1988-07-01 1991-07-16 Marion Merrell Dow Inc. Method of treating bronchoconstriction with 1,3-unsymmetrical straight chain alkyl-substituted 8-phenylxanthines
US5298508A (en) * 1988-07-19 1994-03-29 The United States Of America As Represented By The Department Of Health And Human Services Irreversible inhibitors of adenosine receptors
DE3843117A1 (de) * 1988-12-22 1990-06-28 Boehringer Ingelheim Kg Neue xanthinderivate mit adenosin-antagonistischer wirkung
GB8906792D0 (en) 1989-03-23 1989-05-10 Beecham Wuelfing Gmbh & Co Kg Treatment and compounds
US5047534A (en) * 1990-03-26 1991-09-10 Merrell Dow Pharmaceuticals Inc. Selective adenosine receptor agents
IL100088A (en) * 1990-11-21 1995-07-31 Smithkline Beecham Corp FNT inhibitor preparations containing histogenic transducts converted at positions 1, 3, and 8
US5484920A (en) * 1992-04-08 1996-01-16 Kyowa Hakko Kogyo Co., Ltd. Therapeutic agent for Parkinson's disease
TW252044B (fr) * 1992-08-10 1995-07-21 Boehringer Ingelheim Kg
JP2613355B2 (ja) * 1992-09-28 1997-05-28 協和醗酵工業株式会社 パーキンソン氏病治療剤
US5877179A (en) * 1992-09-29 1999-03-02 The United States Of America As Represented By The Department Of Health And Human Services Xanthines for identifying CFTR--binding compounds useful for activating chloride conductance in animal cells
WO1994025462A1 (fr) * 1993-05-03 1994-11-10 The United States Of America, Represented By The Derives de 1,3,7-trialkyl-xanthine substitues en position 8 utiles comme antagonistes de recepteurs d'adenosine a2 a selectivite
US5504090A (en) * 1994-03-30 1996-04-02 Trustees Of The University Of Pennsylvania Compositions and methods for the prevention and treatment of ischemia-reperfusion organ injury
GB9415529D0 (en) * 1994-08-01 1994-09-21 Wellcome Found Phenyl xanthine derivatives
US6323201B1 (en) 1994-12-29 2001-11-27 The Regents Of The University Of California Compounds for inhibition of ceramide-mediated signal transduction
US6930101B1 (en) 1999-05-17 2005-08-16 The Regents Of The University Of California Thiazolopyrimidines useful as TNFα inhibitors
US6403567B1 (en) 1999-06-22 2002-06-11 Cv Therapeutics, Inc. N-pyrazole A2A adenosine receptor agonists
USRE47351E1 (en) 1999-06-22 2019-04-16 Gilead Sciences, Inc. 2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists
ES2166270B1 (es) * 1999-07-27 2003-04-01 Almirall Prodesfarma Sa Derivados de 8-fenil-6,9-dihidro-(1,2,4,)triazolo(3,4-i)purin-5-ona.
US6815446B1 (en) 1999-08-31 2004-11-09 Vanderbilt University Selective antagonists of A2B adenosine receptors
DE60026559T2 (de) * 1999-10-29 2006-12-14 Kyowa Hakko Kogyo Co., Ltd. Arzneimittel gegen essstörungen
CA2439222C (fr) * 2000-02-23 2009-07-14 Cv Therapeutics, Inc. Procede permettant d'identifier des agonistes partiels du recepteur a2a
US20080318983A1 (en) * 2001-11-09 2008-12-25 Rao Kalla A2b adenosine receptor antagonists
US7317017B2 (en) 2002-11-08 2008-01-08 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
US7125993B2 (en) * 2001-11-09 2006-10-24 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
US6977300B2 (en) * 2001-11-09 2005-12-20 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
CN100467469C (zh) 2001-11-09 2009-03-11 Cv医药有限公司 A2b腺苷受体拮抗剂
BR0302965A (pt) * 2002-02-01 2005-02-09 King Pharmaceuticals Res & Dev Composto e método de tratar doenças mediadas por receptores de adenosina a2b
US8470801B2 (en) 2002-07-29 2013-06-25 Gilead Sciences, Inc. Myocardial perfusion imaging methods and compositions
US20050020915A1 (en) * 2002-07-29 2005-01-27 Cv Therapeutics, Inc. Myocardial perfusion imaging methods and compositions
US7683037B2 (en) * 2002-07-29 2010-03-23 Gilead Palo Alto, Inc. Myocardial perfusion imaging method
JP4929173B2 (ja) * 2004-09-01 2012-05-09 ギリアード・パロ・アルト・インコーポレイテッド Ａ２ｂアデノシンレセプターアンタゴニストを使用する創傷治癒の方法
US7655636B2 (en) 2004-10-20 2010-02-02 Gilead Palo Alto, Inc. Use of A2A adenosine receptor agonists
EP1989214B8 (fr) 2006-02-03 2016-12-21 Gilead Sciences, Inc. Procede de preparation d'un agoniste de recepteur a2a-adenosine et ses polymorphes
EP2056834B1 (fr) * 2006-09-01 2012-08-29 Gilead Sciences, Inc. Méthodes et compositions permettant d'augmenter la tolérabilité de patients pendant des méthodes d'imagerie myocardique
US20090081120A1 (en) * 2006-09-01 2009-03-26 Cv Therapeutics, Inc. Methods and Compositions for Increasing Patient Tolerability During Myocardial Imaging Methods
WO2008042796A2 (fr) * 2006-09-29 2008-04-10 Cv Therapeutics, Inc. Procédés d'imagerie myocardique chez des patients ayant un historique de maladie pulmonaire
WO2008086096A2 (fr) * 2007-01-03 2008-07-17 Cv Therapeutics, Inc. Imagerie de perfusion myocardique
MX2011003168A (es) * 2008-09-29 2011-05-19 Gilead Sciences Inc Combinaciones de un agente de control de cantidad y un antagonista del receptor a-2-alfa para utilizarse en metodos de tomografia computarizada de detectores multiples.

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2840559A (en) * 1954-06-22 1958-06-24 Krantz Jr Nuclearly substituted 8-theophyllines and method of making the same
DE1091570B (de) * 1958-10-23 1960-10-27 Albert Ag Chem Werke Verfahren zur Herstellung von in 8-Stellung substituierten 1, 3-Dialkylxanthinen
GB982079A (en) * 1962-05-01 1965-02-03 Dresden Arzneimittel Process for the production of xanthine derivatives
NL297352A (fr) * 1962-08-31
EP0011399A1 (fr) * 1978-11-11 1980-05-28 FISONS plc Théophyllines-N-substituées, procédés pour leur préparation et compositions pharmaceutiques les contenant
US4452788A (en) * 1982-04-21 1984-06-05 Warner-Lambert Company Substituted 8-phenylxanthines

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4755517A (en) * 1986-07-31 1988-07-05 Warner-Lambert Company Derivatives of xanthine, pharmaceutical compositions and methods of use therefor

Also Published As

Publication number Publication date
CA1234804A (fr) 1988-04-05
GB2135311A (en) 1984-08-30
SE456680B (sv) 1988-10-24
DE3406275A1 (de) 1984-09-27
NL8400514A (nl) 1984-09-17
GB8404243D0 (en) 1984-03-21
FR2541281A1 (fr) 1984-08-24
FR2541281B1 (fr) 1988-01-29
GB2135311B (en) 1986-11-05
SE8400788D0 (sv) 1984-02-14
GB8403574D0 (en) 1984-03-14
JPS59205377A (ja) 1984-11-20
IT8419675A0 (it) 1984-02-17
US4593095A (en) 1986-06-03
IT1196031B (it) 1988-11-10
SE8400788L (sv) 1984-08-19

Similar Documents

Publication Publication Date Title
BE898946A (fr) Nouveaux antagonistes des recepteurs de l'adenosine
ES2141913T3 (es) Agonistas y antagonistas de los receptores de la adenosina a1.
ES2021143B3 (es) Proceso mejorado para preparar composiciones oleaginosas estables.
BR8707609A (pt) Composto aditivo para fluidos funcionais,processo para preparar um composto aditivo,composto aditivo,complexo aditivo,aditivo concentrado,composicao lubrificante,composicao aditiva e composicao combustivel
FI831230L (fi) N-glykosylerade karboxylsyraamidderivat, foerfarande foer deras framstaellning samt deras anvaendnifoer att paoverka kroppens eget foersvar
DK186087D0 (da) Anvendelse af pseudomonsyre til behandling af fungale infektioner
GR79463B (fr)
DK1019426T3 (da) Hidtil ukendte A1-adenosinreceptoragonister og -antagonister
NO872260L (no) Fremgangsmaate for sliping av silisiumkarbid til pulver.
HU9200822D0 (en) 8-substituted purin derivatives actin as selective adenozine receptor
DE3650647T2 (de) Arzneimittel zur Behandlung von Anxietas
DK155321C (da) Analogifremgangsmaade til fremstilling af 3,4,5-trihydroxypiperidinderivater
JPS567763A (en) 22hydroxymethyll3*4*55trihydroxyypiperidine derivative* its manufacture and use
ATE147746T1 (de) Derivate von fluorphosphonat-nukleotiden
BG99638A (en) Derivatives of xanthine as diuretic form
ES2076141T3 (es) 5-aril-3h-1,2,4-triazol-3-onas y su uso como anticonvulsivos.
CA1269383C (fr) Esters herbicides de l'acide 2,6-bis- fluoromethyldihydropyridine-3,5-dicarboxylique
NL7614212A (nl) Modacrylvezels, die stabiel zijn wat betreft hun glans en werkwijze voor het vervaardigen ervan.
ES549983A0 (es) Procedimiento para preparar 6-sustituido-5-feniltetrazol (1,5-a)-(1,2,4)triazol-(1,5-c)pirimidinas
BR8103208A (pt) Compostos quimicos que sao novos derivados de quinoxalina 1,4-dioxido,processo para sua prepacao,composicoes que os contem,concentrado para forragem,processo para preparacao deste concentrado e processo para aumentar o ganho de peso no uso de racoes
ES2056873T3 (es) Derivados de 1-acil-2,3-dihidro-4-(1h)-quinolinona-4-oxima, procedimiento para producirlos y uso de los mismos.
DK359282A (da) Fremgangsmaade til fremstilling af materiale ud fra baelgfrugter
EP0276204A3 (fr) Gamètocides pyridiques
ATE39416T1 (de) Loesungsvermittlerfreie, waessrige nitroglycerinloesung.
AT388731B (de) Neue derivate von benzimidazol, ihre herstellung und verwendung

Legal Events

Date Code Title Description
RE Patent lapsed

Owner name: THE JOHNS HOPKINS UNIVERSITY

Effective date: 19940228